Ceftazidime prescription and antibiotic resistance patterns in a tertiary care hospital
Banan M Aiesh, Shama Amoudi, Leena Bassalat, Abeer Yousef, Dania Abuhalima, Adham Abutaha, Samah W Al-Jabi, Ali Sabateen, Sa’ed H Zyoud · 2025
Read Ceftazidime prescription and antibiotic resistance patterns in a tertiary care hospital by Banan M Aiesh, Shama Amoudi, Leena Bassalat, Abeer Yousef, Dania Abuhalima, Adham Abutaha, Samah W Al-Jabi, Ali Sabateen, Sa’ed H Zyoud (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12706030.txt.
Description
Banan Aiesh and eight co-authors review use of a strong antibiotic in a hospital in the West Bank in a 2025 study. The drug, ceftazidime, treats infections from a broad class of bacteria, but resistance is rising. The team studied five hundred fifty eight inpatients treated with the drug by vein between 2021 and 2023.
Most use was in cancer care, for fever during low white cell counts and for pneumonia. Most patients were discharged, though about a fifth needed stronger therapy later. The most common germ found was a gut bacterium, and nearly half of its samples resisted the drug. Cancer type, diabetes, and liver disease shaped outcomes in their analysis.
Catalog record
| CREATOR | Banan M Aiesh, Shama Amoudi, Leena Bassalat, Abeer Yousef, Dania Abuhalima, Adham Abutaha, Samah W Al-Jabi, Ali Sabateen, Sa’ed H Zyoud |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |